

North Central Cancer Treatment Group

N0177: Pilot and Phase II Trial of Temozolomide, OSI-774 and Radiation in
Glioblastoma Multiforme Patients

Status Change – March 8, 2005

NOTICE OF STATUS CHANGE

Study 1, Dose Level 1D, will reopen to non EIAC patients to accrue two additional patients
accrual effective **March 8, 2005**.

Please retain this notice with the protocol.